

REMARKS

Restriction Requirement

Claims 1-95 were originally presented for examination and were subjected to restriction into six groups. Applicants hereby elect Group III, without traverse. Accordingly, claims 1-25, 27-66, 72-74 and 80-94 are cancelled and claim 26 is amended to change its dependency so that it is included in elected Group III, and to correct a typographical error. As a result of this amendment, claims 26, 67-71, 75-79 and 95 are presently pending.

Species election

In response to the species election requirements, Applicants elect the VOP32E protein (see Table 3). Applicants further elect activation of VEGF expression and stimulation of angiogenesis. Applicants note that upon indication of an allowable species claim, they are entitled to examination of generic claims for proteins that modulate angiogenesis, and for methods of modulating angiogenesis (both stimulation and inhibition).

All pending claims read on all elected species.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 415-576-0300
JOL:pfh
PA 3297794 v1